ArticleDiscover oncology2025
Unraveling the molecular landscape of pancreatic cancer: a systems biology approach to identify therapeutic targets.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to late diagnosis and limited treatment options for pancreatic ductal adenocarcinoma (PDAC), identifying novel therapeutic targets is crucial to improving patient outcomes. This study aims to analyze differentially expressed genes (DEGs) in PDAC, identify key hub genes through protein-protein interaction (PPI) network analysis, and propose potential therapeutic targets using drug analysis databases.
methodsGene expression data were obtained from the Gene Expression Omnibus (GEO) database (GSE101448). Gene ontology (GO) and pathway enrichment analyses were conducted using the Enrichr database. The STRING database was used to construct the PPI network, and hub genes were identified via Cytoscape’s CytoHubba plugin. Promoter analysis of hub genes was conducted using the Tomtom and GOMO tools to identify transcription factors potentially regulating these genes. Cytocluster analysis was performed to identify functional clusters within the protein interaction network. Drug target analysis was conducted through the DrugBank database to identify potential therapeutic compounds for the identified hub genes.
resultsFifteen hub genes were identified, including TP53, FN1, SRC, PTPRC, CD8A, RRM2, KIF20A, AURKA, CCNB1, BUB1, CDCA3, FAM83D, PIMREG, CDCA2, and CKAP2L. Promoter analysis revealed key transcription factors involved in the regulation of these genes, suggesting their role in PDAC progression. Drug analysis revealed several promising therapeutic candidates, such as Nutlin-3, Siremadlin, Dasatinib, Clofarabine, and Ocriplasmin, which target key regulatory pathways involved in tumor progression and cell cycle dysregulation.
conclusionThis study provides valuable insights into the molecular mechanisms underlying pancreatic cancer and identifies potential drug candidates targeting key regulatory genes. Further experimental validation and clinical trials are needed to assess the effectiveness of these identified therapeutic options in improving PDAC treatment outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.